AstraZeneca versus Pfizer Online publication date: Tue, 03-Sep-2019
by Asja Hot; Matthias Mählitz; Patrizia Wien-Nicolini; Roman Stegmüller
European J. of International Management (EJIM), Vol. 13, No. 5, 2019
Abstract: The Pfizer-AstraZeneca case shows how an acquisition target can successfully repel an attempted takeover by engaging with positively disposed stakeholders and managing communications and the news agenda. The company communicated clearly, consistently and powerfully throughout the process and could benefit from a natural, if temporary, coalition of interests between the UK scientific establishment, unions, and a significant portion of the media. In the end, they were able to persuade enough major shareholders to support their vision and reject Pfizer's offer. AstraZeneca presented themselves as a local champion, a cornerstone of Britain's high-tech industry, a key investor, valuable employer and in general, a standard bearer for the high-tech, value-added industry that was at that time being actively championed by the UK Government. At the same time, they characterised Pfizer's approach as an example of greed-driven capitalism most clearly demonstrated by their interests in the tax conversion possibilities.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the European J. of International Management (EJIM):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook